Crossref
Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma
European Journal of Cancer · 2026-11 · 248 · 117522
DOI: 10.1016/j.ejca.2026.117522 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von H.J. Li und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, H., Zi-Ling, L., Pei-Ihen, W., Nicola, M., Kuo-Yen, H., & Pan-Chyr, Y. (2026). Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma. European Journal of Cancer, 248, 117522. https://doi.org/10.1016/j.ejca.2026.117522
Vancouver
Li H, Zi-Ling L, Pei-Ihen W, Nicola M, Kuo-Yen H, Pan-Chyr Y. Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma. European Journal of Cancer. 2026;248:117522. doi:10.1016/j.ejca.2026.117522
BibTeX
@article{Li2026,
author = {Li, H.J. and Zi-Ling, L. and Pei-Ihen, W. and Nicola, M. and Kuo-Yen, H. and Pan-Chyr, Y.},
title = {Repurposing of HTS-10 to Overcome C797S-Mediated Osimertinib Resistance in EGFR-Mutant Lung Adenocarcinoma},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117522},
doi = {10.1016/j.ejca.2026.117522}
}
EUVIMED